1477 — Ocumension Therapeutics Share News
0.000.00%
Last trade - 00:00- HK$3.71bn
- HK$3.43bn
- CNY804.35m
Brief: Ocumension Therapeutics Posts HY Adjusted Net Loss RMB125.9 Million
Brief: Ocumension Therapeutics Says Clinical Trial Authorization For Initiating Phase III Clinical Trial Of Ot-101-S Accepted
Brief: Ocumension Therapeutics Says Ot-1001 (Zerviate) Included In Priority Review Of PRC's Nmpa
Brief: Ocumension Therapeutics Says New Drug Application For Ot-1001 (Zerviate), Accepted By China NMPA
Brief: Ocumension Therapeutics Posts FY Loss RMB402.6 Mln
Shandong Boan Biotechnology hits record high on drug's commercialization hope
Brief: Ocumension Therapeutics Completes Patient Enrollment In Phase III Clinical Trial Of OT-702
China's Ocumension Therapeutics jumps on robust earnings outlook
Brief: Ocumension Therapeutics Sees Total Rev Of About RMB155.0 Mln To RMB159.0 Mln For Year
Brief: Ocumension Therapeutics - Revenue Increased Rmb54.5 Million For Six Months, Up 162.1%
Brief: Ocumension Therapeutics Says NDA For Ot-401 Approved By Center For Drug Evaluation Of NMPA
Brief: EyePoint Pharma And Ocumension Therapeutics Announce Approval Of Yutiq By China's NMPA
Brief: Ocumension Therapeutics Says Approval Received For A Phase III Clinical Trial Of Ot-703 In China
Brief: Ocumension Therapeutics Says Unit Enters Promotion Agreement With Viatris Pharmaceuticals
Brief: Ocumension Therapeutics Posts FY Adjusted Net Loss Non-IFRS Adjustment RMB187.0 Mln
Brief: Ocumension Therapeutics Says It Got Positive Results From Phase III Clinical Trial Of OT-1001
Brief: Ocumension Therapeutics Entered Series Of Cooperation Arrangements With Viatris Pharmaceuticals
Brief: Nicox Says Ocumension Get Positive Phase 3 Clinical Trial Results For Zerviate In China
Brief: Nicox Says First Patient Screened In China For Denali Trial